Walleye Capital LLC Biogen Inc. Transaction History

Walleye Capital LLC

$54.6 Billion
Q1 2024

A detailed history of Walleye Capital LLC transactions in Biogen Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 65,800 shares of BIIB stock, worth $15 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

65,800

Previous 46,000 43.04%

Holding current value

$15 Million

Previous $11.9 Million 19.2%

% of portfolio

0.03%

Previous 0.03%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$212.02 - $267.71 $2.03 Million - $2.57 Million	9,584 New	9,584 $2.07 Million
Q3 2023 Nov 14, 2023	SELL	$253.3 - $285.89 $3.36 Million - $3.79 Million	-13,250 Reduced 90.21%	1,438 $369,000
Q2 2023 Aug 14, 2023	BUY	$275.25 - $318.06 $273,598 - $316,151	994 Added 7.26%	14,688 $4.18 Million
Q1 2023 May 15, 2023	SELL	$256.56 - $292.34 $5.34 Million - $6.08 Million	-20,803 Reduced 60.3%	13,694 $3.81 Million
Q4 2022 Feb 14, 2023	BUY	$252.44 - $306.72 $8.71 Million - $10.6 Million	34,497 New	34,497 $9.55 Million

Q2 2022 Aug 08, 2022	SELL	$187.54 - $223.02 $316,004 - $375,788	-1,685 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$193.77 - $244.14 $326,502 - $411,375	1,685 New	1,685 $355,000
Q2 2020 Aug 14, 2020	SELL	$258.66 - $342.55 $46,558 - $61,659	-180 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$268.85 - $341.04 $8,065 - $10,231	-30 Reduced 14.29%	180 $57,000
Q4 2019 Feb 14, 2020	SELL	$220.06 - $304.07 $735,440 - $1.02 Million	-3,342 Reduced 94.09%	210 $62,000
Q3 2019 Nov 14, 2019	BUY	$217.44 - $243.88 $737,556 - $827,240	3,392 Added 2120.0%	3,552 $827,000
Q2 2019 Aug 14, 2019	SELL	$219.29 - $241.72 $313,803 - $345,901	-1,431 Reduced 89.94%	160 $37,000
Q3 2018 Nov 14, 2018	BUY	$293.51 - $383.83 $466,974 - $610,673	1,591 New	1,591 $562,000

Others Institutions Holding BIIB

# of Institutions

1,047

Shares Held

126M

Call Options Held

1.37M

Put Options Held

1.35M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $32.8B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.

Account

Walleye Capital LLC Biogen Inc. Transaction History